FarberRSHarelALublinF. Novel agents for relapsing forms of multiple sclerosis. Annu Rev Med2016; 67: 309–321.
2.
AlmeidaKJBarreto-SoaresRVCampos-SausaRNet al. Pulmonary paracoccidioidomycosis associated with use of natalizumab in multiple sclerosis. Multiple Scler J, this issue.
3.
GreensteinJ. Diffuse dermatophytosis occurring on dimethylfumarate therapy. Multiple Scler J, this issue.
4.
LinkerRALeeDHRyanSet al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011; 134: 678–692.
5.
DubeyDKieseierBCHartungHPet al. Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother2015; 15: 339–346.
6.
YednockTACannonCFritzLCet al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
7.
NinoMBodnerCSimardMLet al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol2006; 59: 748–754.
8.
RomaniL. Immunity to fungal infections. Nature Rev Immunol2011; 11: 275–288.
9.
HauCSTadaYKandaNet al. Immunoresponses in dermatomycoses. J Dermatol2015; 42: 236–244.
10.
JaradatSWCubillosSKriegNet al. Low DEFB4 copy number and high systemic HBD-2 and IL-22 levels are associated with dermatophytosis. J Invest Dermathol2015; 135: 750–758.
11.
Shikanai-YasudaMAMendesRPLopes ColomboAet al. Brazilian guidelines for the clinical management of paracoccidioidomycosis. Rev Soc Bras Med Trop2017; 50: 715–740.
12.
McGinleyMPMossBPCohenJA. Safety monoclonal antibodies for the treatment of multiple sclerosis. Expert Opin Drug Saf2017; 16: 89–100.
